BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23749913)

  • 1. Carboxy-terminal telopeptide (CTX) and amino-terminal propeptide (PINP) of type I collagen as markers of bone metastases in patients with non-small cell lung cancer.
    Lumachi F; Santeufemia DA; Del Conte A; Mazza F; Tozzoli R; Chiara GB; Basso SM
    Anticancer Res; 2013 Jun; 33(6):2593-6. PubMed ID: 23749913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
    Ebert W; Muley T; Herb KP; Schmidt-Gayk H
    Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D; Siepmann S; Geppert R; Wernecke KD; Possinger K; Lüftner D
    Anticancer Res; 2007; 27(4A):1853-62. PubMed ID: 17649784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
    Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
    Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum N-telopeptide of type I collagen and bone alkaline phosphatase and their relationship in patients with non-small cell lung carcinoma and bone metastases. Preliminary results.
    Lumachi F; Marino F; Fanti G; Chiara GB; Basso SM
    Anticancer Res; 2011 Nov; 31(11):3879-81. PubMed ID: 22110213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preoperative serum pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen level predicts postoperative distant metastasis in patients with non-small-cell lung cancer.
    Tanaka Y; Yoshimasu T; Oura S; Hirai Y; Kawago M; Ikeda M; Okamura Y
    Eur J Cardiothorac Surg; 2013 Sep; 44(3):539-43; discussion 543. PubMed ID: 23435520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
    Tähtelä R; Thölix E
    Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
    Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
    Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis.
    Koizumi M; Takahashi S; Ogata E
    Anticancer Res; 2003; 23(5b):4095-9. PubMed ID: 14666607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
    Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
    Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
    Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
    J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
    Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
    Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical usefulness of cross-linked N-telopeptide of type I collagen (NTx) as a bone metastatic marker in patients with prostate cancer--comparison with serum PICP, PINP and ICTP].
    Kobayashi Y; Ochi M; Tokue A
    Hinyokika Kiyo; 2000 Dec; 46(12):869-72. PubMed ID: 11211802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of serum cytokeratin 19 fragment (CYFRA 21-1) and carcinoembryonic antigen (CEA) as tumour markers for non-small cell lung cancer.
    Chantapet P; Riantawan P; Lebnak P; Getngern P
    J Med Assoc Thai; 2000 Apr; 83(4):383-91. PubMed ID: 10808698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Centre-independent detection of non-small cell lung cancer (NSCLC) by means of classification with receiver operating characteristic (ROC)-based data transformation.
    Bitterlich N; Muley T; Schneider J
    Anticancer Res; 2010 May; 30(5):1661-5. PubMed ID: 20592358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non-operable lung cancer.
    Holdenrieder S; Von Pawel J; Duell T; Feldmann K; Raith H; Schollen A; Nagel D; Stieber P
    Anticancer Res; 2010 May; 30(5):1855-62. PubMed ID: 20592392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical significance of serum bone metabolic markers in diagnosis and monitoring of myeloma bone disease].
    Peng F; Fu R; Liu H; Wang Y; Ding K; Ding S; Liu Z; Ruan E; Qu W; Wang H; Xing L; Wang X; Wang G; Song J; Wu Y; Li L; Liu H; Guan J; Shao Z
    Zhonghua Yi Xue Za Zhi; 2015 Nov; 95(42):3436-9. PubMed ID: 26813134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone turnover markers in women with early stage breast cancer who developed bone metastases. A prospective study with multivariate logistic regression analysis of accuracy.
    Lumachi F; Basso SM; Camozzi V; Tozzoli R; Spaziante R; Ermani M
    Clin Chim Acta; 2016 Sep; 460():227-30. PubMed ID: 27404457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.